KLOT-1123
Phosphate wasting disorders (e.g., hypophosphatemic rickets, CKD)
Pre-clinicalActive
Key Facts
Indication
Phosphate wasting disorders (e.g., hypophosphatemic rickets, CKD)
Phase
Pre-clinical
Status
Active
Company
About EPOK Therapeutics
EPOK Therapeutics is a newly formed, private biotech focused on developing next-generation biologic therapies for metabolic disorders, particularly those related to chronic kidney disease (CKD). The company leverages over two decades of antibody engineering expertise to create targeted therapies for anemia and phosphate wasting disorders. Its initial pipeline features two lead preclinical candidates: EPRA-0322 for anemia and KLOT-1123 for phosphate-related disorders. As a pre-revenue, preclinical-stage company, EPOK's strategy centers on advancing these programs through development to address significant unmet needs in nephrology and metabolic disease.
View full company profile